References
- Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007;67:1803–12
- Richardson MD. Changing patterns and trends in systemic fungal infections. J antimicrob Chemother 2005;56(1 Suppl):i5–11
- Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009;66:1711–7
- Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26–34
- Menzin J, Meyers JL, Friedman M, et al. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control 2011;39:e15–20
- Jansen JP, Kern WV, Cornely OA, et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006;9:12–23
- Greiner RA, Meier Y, Papadopoulos G, et al. Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland. Oncology 2010;78:172–80
- Michallet M, Gangneux JP, Lafuma A, et al. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system. J Med Econ 2011;14:28–35
- Grau S, de la Camara R, SanzM, et al. Cost-effectiveness of posaconazole versus standard azole treatment (fluconazole or itraconazole) in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain. Abstract presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases; 2008 Apr 19–22; Barcelona, Spain
- Stam WB, O’Sullivan AK, Rijnders B, et al. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 2008;81:467–74
- Dranitsaris G, Khoury H. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. Support Care Cancer 2011;19:1807–13
- Lyseng-Williamson K. Posaconazole. A pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. Pharmacoeconomics 2011;29:251–68
- Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335–47
- Cornely OA, Maertens J, Winston DJ, et al. Posaconazole versus fluconazole ore itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348–59
- O'Sullivan AK, Pandya A, Papadopoulos G, et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health 2009;12:666–73
- National Cancer Institute. SEER Cancer Statistics Review 1975–2003. Age-adjusted SEER incidence and US death rates and 5-year relative survival rates. 2006. Available at http://seer.cancer.gov/csr/1975_2003/results_single/sect_01_table.04_2pgs.pdf; Accessed July 12 2012
- Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006;106:1099–109
- Ministry of Health. Official price bulletins. http://www.yyka.gov.gr/articles/times-farmakwn/deltia-timwn. Accessed July 2012
- Thalheimer M, Cornely OA, Hoppe-Tichy T, et al. Pharmaco- economic analysis of posaconazole versus standard azole prophylaxis in high-risk neutropenic AML/MDS patients in Germany. Abstract presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases; 2008 Apr 19-22; Barcelona, Spain
- Maertens M, Aoun M, Bron D, et al. Cost-effectiveness of posaconazole (Noxafil) versus standard azole therapy in the prevention of invasive fungal infections among high-risk neutropenic patients in Belgium. Abstract presented at the 10th International Symposium on Febrile Neutropenia; 2008 Feb 8–9; Brussels, Belgium
- Suchankova E, Dolezal T, Simonova J. Cost-effectiveness of antifungal prophylaxis with posaconazole versus standard azole therapy in the prevention of invasive fungal infections among high risk haematology patients in Czech Republic. Value Health 2009;12:A380
- Jansen JP, Kern WV, Cornely OA, et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006;9:12–23